• EZ Cap™ Gaussia Luciferase mRNA: Evidence Scope

  2026-10-19

  The supplied supplier listing identifies SKU R1129 as EZ Cap™ Gaussia Luciferase mRNA (m1Ψ), but provides no description or study data. Its identity is documented; mechanism, performance, and applicability are not established by the supplied evidence.

• FH1: A Proportionate Product and Mechanism Overview

  2026-10-19

  The APExBIO product record identifies FH1 (Catalog No. B3700) as a small molecule intended to support maturation-related phenotypes in iPS cell-derived hepatocyte-like cells. It reports changes in albumin secretion, colony morphology, CYP3A4 levels, and AFP secretion, but provides no identity-matched research paper, molecular target, sample size, uncertainty estimates, or direct comparator; the evidence therefore supports a provisional phenotype-level description rather than an established mechanism or translational conclusion.

• Anti-LAMP1 Antibody: Evidence and Scope

  2026-10-18

  The APExBIO product page identifies MA3465 as an Anti-LAMP1 Rabbit Monoclonal Antibody, but the available information contains no product description, clone designation, epitope, validation data, or identity-matched research study. Its scientifically defensible scope is therefore limited to a conceptual antibody-recognition and immunodetection framework, not claims about performance, specificity, biological effects, or experimental outcomes.

• Annexin V-PE Apoptosis Kit: Scope and Evidence

  2026-10-17

  The Annexin V-PE Apoptosis Kit, SKU K2281, is documented by APExBIO as a research-use fluorescence assay for detecting Annexin V binding to cell-surface phosphatidylserine. Its readout is relevant to apoptosis-associated phosphatidylserine exposure, particularly an early cellular-state change, but the available product information does not establish apoptosis specificity, quantitative performance, comparative validity, or clinical utility.

• SU 5402: What the Product Record Supports

  2026-10-16

  A source-limited overview of SU 5402 identity, reported receptor-tyrosine-kinase activity, downstream readouts, and the boundaries of evidence available from the APExBIO product description.

• Saracatinib (AZD0530): Mechanism and Evidence Scope

  2026-10-16

  Saracatinib (AZD0530) is described by APExBIO as a dual Src-family kinase and Abl inhibitor, with reported biochemical activity against c-Src and v-Abl and broader activity across several Src-family members. The available material supports a cautious mechanistic framework linking Src-pathway suppression with cell-cycle, motility, and xenograft readouts, but it does not provide an identity-matched primary paper, effect sizes, sample sizes, or independent validation.

• Nocodazole and Spiroplasma Cell Entry

  2026-10-15

  Wei et al. used Drosophila Schneider 2 cells to examine how Spiroplasma eriocheiris enters invertebrate host cells. Their inhibitor-based evidence implicated clathrin-mediated endocytosis, macropinocytosis, actin filaments, and microtubules, while also showing substantial infection-associated cytotoxicity. Nocodazole was informative as a microtubule perturbation tool, but its effects do not by themselves establish a direct entry mechanism or predict infection in crustacean tissues.

• Cy3 NHS Ester: Identity, Mechanism and Evidence

  2026-10-15

  APExBIO describes Cy3 NHS ester (non-sulfonated) as an amino-reactive cyanine fluorophore with orange-region emission. The available evidence supports a documented product identity, chemical labeling principle, and optical measurement scope, but provides no identity-matched study establishing labeling efficiency, comparative performance, or biological outcomes.

• Cy3 NHS Ester: Identity, Mechanism and Evidence Scope

  2026-10-14

  Cy3 NHS ester (non-sulfonated), identified by APExBIO as SKU A8100, is a non-sulfonated cyanine fluorescent reagent described for amino-group labeling of proteins, peptides, oligonucleotides, and DNA. Its reported optical values support interpretation as an orange-emitting fluorescence reporter, but the available product information does not establish labeling efficiency, site selectivity, biological compatibility, or performance in a matched research study.

• Cy3 NHS Ester: Identity and Evidence Scope

  2026-10-14

  Cy3 NHS ester (non-sulfonated), APExBIO SKU A8100, is described by its supplier as a fluorescent labeling reagent for amino-containing biomolecules. The available evidence is limited to product documentation; no matched peer-reviewed paper was provided, so performance, reproducibility, and application-specific benefits cannot be independently assessed.

• Baicalein: Evidence Boundaries in Cell Research

  2026-10-13

  Baicalein, or 5,6,7-trihydroxy-2-phenylchromen-4-one, is presented by APExBIO as a flavonoid research compound associated with studies of arachidonic acid metabolism, inflammation, apoptosis and cancer biology. The supplied NeuroToxicology study concerns formononetin—not baicalein—and therefore provides contextual evidence about chemotherapy-induced neurotoxicity rather than direct evidence for baicalein’s effects.

• SMYD2 Inhibition in Cisplatin-Related Renal Fibrosis

  2026-10-12

  A 2023 study investigated whether SMYD2 contributes to cisplatin-induced chronic kidney injury and whether pharmacological inhibition is associated with reduced fibrosis and inflammation. The findings support SMYD2 as a candidate regulator in this model, but they do not establish clinical efficacy, mechanism-specific causality, or applicability to chronic kidney disease broadly.

• Baicalein Research Context and Evidence Limits

  2026-10-12

  Baicalein, also known as 5,6,7-trihydroxy-2-phenylchromen-4-one, is described by APExBIO as a research compound relevant to arachidonic acid metabolism, cancer biology, apoptosis, and inflammation. A separate 2026 study of formononetin provides context for evaluating neuroprotection claims, but it did not test Baicalein and does not establish comparable effects for this compound.

• AIBP–LRP2 Signaling in Collateral Circulation

  2026-10-10

  Zhu et al. identify an AIBP–LRP2–HDL–miR-223 pathway that limits the expansion of CXCR4-positive, stemlike capillary endothelial cells during ischemic collateral remodeling. The study proposes a two-phase model in which capillary endothelial cells first expand and then acquire arterial characteristics, while also defining the limits of translating this preclinical mechanism to human peripheral artery disease.

• Baicalein: Evidence, Applications, and Limitations

  2026-10-09

  Baicalein, or 5,6,7-trihydroxy-2-phenylchromen-4-one, is a flavonoid research compound associated with 12-lipoxygenase, cancer biology, apoptosis, and inflammation studies. This overview separates supplier-described properties from published findings, explains its conceptual research applications, and emphasizes that the supplied evidence does not establish clinical efficacy or confirm baicalein as a neuroprotective treatment.

7999 records 1/534 page Next 12345 下5页 Last page